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Abstract Introduction: Physical exercise has gained increasing focus as a potential mean to maintain cogni-
tive function in patients with Alzheimer’s disease (AD). Alongside themarkers of specific AD pathol-
ogy (amyloid b and tau), other pathologies such as neuronal damage and synaptic loss have been
proposed as markers of the disease. Here, we study the effect of physical exercise on biomarkers
of neuronal and synaptic integrity.
Methods: Cerebrospinal fluid (CSF) from 51 AD subjects who participated in the randomized
controlled trial Preserving Cognition, Quality of Life, Physical Health and Functional Ability in Alz-
heimer’s Disease: The Effect of Physical Exercise (ADEX) was analyzed for the concentration of
neurofilament light (NFL), neurogranin (Ng), visinin-like protein-1 (VILIP-1), and chitinase-3–
like protein 1 (YKL-40). Participants were subjected to either 16 weeks of moderate- to high-
intensity exercise (n 5 25) or treatment as usual (control group, n 5 26), and CSF was collected
before and after intervention.
Results: No significant differences in CSF concentrations of VILIP-1, YKL-40, NFL, and Ng were
observedwhen comparingmean change from baseline between the exercise and control groups. Simi-
larly, when classifying subjects based on their exercise levels, no significant changes were observed
for the biomarkers in the control group compared with the high-exercise group (attending 80% of the
exercise sessions with an intensity of 70% of maximum heart rate or above).
Discussion: These results are not supportive of a modulatory effect of physical exercise on the
selected biomarkers of neuronal and synaptic integrity in patients with AD.
 2017 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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1. Introduction
The molecular pathological mechanisms behind
Alzheimer’s disease (AD) have been studied for decades.
Although the exactmechanisms are still not quite clear, accu-
mulation of amyloid b 42 (Ab42) is an early pathological
hallmark that interacts with and/or promotes neurodegenera-
tion without being directly linked to clinical symptoms [1].
One key feature of neurodegeneration in AD is neuronal
and synaptic loss that better reflects AD progression and
cognitive decline [1–3]. Studies in transgenic animals
suggest effects of physical exercise on neurogenesis,
cognition, and amyloid deposition [4]. Further, epidemiolog-
ical studies suggest that higher physical activity may reduce
the risk of dementia in late life [5], and some intervention
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studies in elderly suggest that participation in physical
activity and cognitive training may reduce future cognitive
decline [6]. However, these studies have investigated
possible effects on risk of dementia and cognitive decline
in general and have not used any biomarkers to diagnose
AD or specifically study effects on AD pathophysiology.
Furthermore, in an effort to arrest the decline in cognitive
function (CF) and loss of activities of daily living,
nonpharmacological approaches have been investigated. In
the randomized clinical trial “Preserving Cognition, Quality
of Life, Physical Health and Functional Ability in
Alzheimer’s Disease: The Effect of Physical Exercise
(ADEX) study,” we analyzed the effect of 16 weeks
moderate- to high-intensity physical exercise (EXE) in
patients with AD on a cognitive [7], functional [8], and
molecular level [9]. Despite some effect on clinical
symptoms such as processing speed and neuropsychiatric
symptoms [7], we found no effect of EXE on levels of Ab,
tau, and phosphorylated tau (p-tau) in cerebrospinal fluid
(CSF) [9]. Therefore, we sought to investigate downstream
molecular processes that potentially could be influenced by
EXE. In this study, we investigated the effect of EXE on
molecular markers of AD neurodegeneration in CSF from
patients with AD participating in the ADEX study. This is
not a study on the potential diagnostic value of these markers
as in cross-sectional study, however an explorative study on
modulating effects of selected markers on exercise.
Neurofilament light (NFL) is a marker of damage to
large-caliber myelinated axons, and elevated CSF levels
have been associated with cognitive deterioration and
structural changes in the white matter and brain atrophy in
patients with AD [10]. Elevated CSF NFL is not a specific
AD marker, and CSF NFL levels do not correlate with
Ab42 levels, indicating that the changes in NFL are not
driven by Ab42 pathology [10]. Similar to NFL, CSF
neurogranin (Ng) levels do not correlate with Ab42 levels
in patients with mild cognitive impairment (MCI) and AD
[11,12]. The synaptic protein Ng is released to the CSF
from the synapses, which is an early event in the
pathogenesis of AD. This also makes Ng a candidate
marker for early AD diagnosis. Alongside this, Ng
possesses the ability to differentiate patients with MCI who
progress to AD (elevated Ng levels) and patients with MCI
who remain stable (low levels of Ng) [11,12]. Just as Ng,
the biomarker visinin-like protein-1 (VILIP-1) has shown
potential as a marker of MCI progression to AD [3].
VILIP-1 is abundantly expressed in the brain and is
excessively released because of neuronal degradation [13].
Although increased CSF levels of VILIP-1 are not specific
to AD, they have shown to correlate well with AD
progression and pathology [3]. Themicroglia derived protein
YKL-40’s role in AD is not fully elucidated. It is speculated
that YKL-40 increases with neuroinflammation [14].
However, apart from AD, increased levels have been found
in CSF after stroke, other neurological disorders, and
normal aging [14–17]. This indicates that YKL-40 is more
a general marker of neuroinflammation/astroglial activation
secondary to many different etiologies, including Ab
pathology [18].
We hypothesized that the concentrations of markers of
neuronal and synaptic damage and astroglial activation
would decrease in CSF in patients with AD as an effect of
moderate- to high-intensity EXE, because of stabilizing ef-
fects of EXE on neurons, synapses, and astrocytes, resulting
in less neurodegeneration and inflammation and thereby lead
to less release of the selected biomarkers in CSF.
2. Methods
2.1. Study population
Two-hundred community-dwelling patients with clini-
cally diagnosed mild AD according to National Institute of
Neurological and Communicative Disorders and Stroke and
the Alzheimer’s Disease and Related Disorders Association
(NINCDS-ADRDA) criteria [19] and a Mini-Mental State
Examination.19 were included and randomized to either a
control group with treatment as usual or a 16-week 60-
minute three times per week moderate- to high-intensity aer-
obic physical exercise (treadmill, stationary bike, and cross-
trainer) group, in groups of four to six subjects per group
with an educated trainer. For detailed description of the inter-
vention used and study participant enrollment, see Hoffmann
et al. [7, 20]. All subjects donated a blood sample before and
after intervention and were tested at baseline and at 16 week
follow-up with a comprehensive battery of tests of CF, activ-
ities of daily function, quality of life, physical activity, and
neuropsychiatric symptoms. For details of inclusion and
exclusion criteria, methods for inclusion, and cognitive and
physical tests, see Steen Jensen et al. [9]. A subgroup of 56
subjects recruited from three of eight centers had a lumbar
puncture performed to collect CSF samples before and after
intervention. Samples where centrifuged on acquisition at
2000 g and stored in 250 mL aliquots at 280C until use.
The baseline characteristics of the study population can be
seen in Table 1.
2.2. Samples
CSF samples from 51 patients of the 56 possible CSF
samples, subjected to 16 weeks of moderate- to high-
intensity EXE (exercise group) or treatment as usual (control
group), were analyzed for the concentration of Ng (UniProt
#: Q92686), VILIP-1 (UniProt #: P62760), NFL (UniProt #:
P07196), and YKL-40 (UniProt #: P36222), at baseline and
16 weeks follow-up.
2.3. Assays
CSF Ng concentration was measured using a previously
published in-house Meso Scale Discovery assay as pub-
lished in Kvastberg et al. [21] and De Vos et al. [22].
Commercially available kits were used for measuring the
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concentrations of VILIP-1 (Human VILIP-1 ELISA; Bio-
Vendor GmbH, Heidelberg, Germany), NFL (NF-light
ELISA; IBL international, Hamburg, Germany), and YKL-
40 (Quantikine ELISA Human Chitinase-3–like 1; R&D
systems, MN, USA) by following the manufactures enclosed
procedure, in technical duplicates. All measurements per
assay were performed in one round of experiments using
one batch of reagents for each biomarker by board-
certified laboratory technicians who were blinded to clinical
data.
2.4. Statistics
The baseline characteristics were compared between the
two groups using t-tests. The baseline versus follow-up con-
centrations were analyzed using paired t-test within each
group, respectively, and the mean change from baseline in
CSF biomarker concentrations was analyzed by Student
t-test. These analyses were done both as an intention-to-
treat analysis where all participants were analyzed and as a
per-protocol analysis where only the subjects that exercised
with a mean intensity of .70% of maximal heart rate (HR)
and attended. 80% of the sessions (high-exercise subjects)
were included. The significance level was set to .05. No post
hoc statistics were used.
3. Results
There were no significant differences in baseline charac-
teristics between control and intervention groups (both all
and high-exercise subjects) and in concentrations of
VILIP-1, NFL, Ng, and YKL-40 in CSF between the inter-
vention group and control group (Table 1). Furthermore,
there was no significant difference at baseline between con-
trol and the high-exercise group with regard to the concen-
trations of VILIP-1, NFL, Ng, and YKL-40, as shown in
Table 1. There was no statistical significant difference in
the concentration of the biomarkers in CSF between baseline
and 16 week follow-up in the two groups, respectively, see
Fig. 1, or in means change from baseline comparing the
two groups. Fig. 2 displays the relative difference between
the groups in percent ([follow-up minus baseline]/baseline)
! 100 in the biomarkers measured. In three out of four bio-
markers analyzed, there was a trend in relative change from
baseline toward an increased level in CSF after 16 weeks of
intervention in the exercise group. However, the variation in
the changes in both groups was large. From the controls,
group coefficient of variation (CV) was calculated for each
assay, to check assay stability. The assay CV ranged from
3% to .30% (NFL: 17.9, Ng: 8.6, YKL-40: 2.9, and
VILIP-1: 32.3).
4. Discussion
In this study, we investigated the effect of an intervention
of 16 weeks of moderate- to high-intensity EXE in patients
with AD on selected biomarkers of neuronal and synaptic
integrity and neuroinflammation. The biomarkers investi-
gated in this study are all found in CSF under normal phys-
iological conditions, and the levels found correspond well
with findings in previous studies [10,14,16,23].
Table 1
Baseline characteristics of the study cohort
Controls (n 5 26) Intervention (n 5 25) P-value* High exercise (n 5 16) P-valuey
Age, yz 68.9 (8.05) 68.2 (6.94) .211x 68.3 (7.71) .60x
Gender, n (%) .15k .13k
Male 19 (73) 13 (52) 8 (50)
Female 7 (27) 12 (48) 8 (50)
Characteristics
Disease duration, yz 1.7 (1.09) 1.1 (0.97) .11x 1.3 (1.00) .23x
MMSEz 25.4 (3.66) 25.4 (2.96) .29x 24.9 (2.80) .16x
Education level, yz 13.0 (2.96) 13.4 (2.81) .622x 13.4 (2.73) .665x
BMI 23.3 (3.56) 25.3 (4.42) .24x 25.1 (4.37) .21x
Medication
Alzheimer’s medication users 23 25 .08k 16 .216k
Antidepressive users 6 5 .789k 3 .945k
Antipsychotic users 1 0 .322k 0 .612k
Baseline outcome measurez
NFL (pg/mL) 1494.9 (634.85) 1392.1 (467.19) .42x 1487.3 (469.89) .45x
Ng (pg/mL) 524.4 (292.66) 628.2 (338.68) .42x 660.3 (371.27) .25x
YKL-40 (ng/mL) 168.4 (66.7) 181.0 (11.8) .28x 187.7 (17.2) .16x
VILIP-1 (pg/mL) 98.5 (70.3) 113.1 (74.1) .95x 111.1 (73.9) .83x
Abbreviations: BMI, body mass index; MMSE, Mini-Mental State Examination; NFL, neurofilament light; Ng, neurogranin; YKL-40, chitinase-3–like pro-
tein 1; VILIP-1, visinin-like protein-1.
*Controls versus intervention.
yControls versus high exercise.
zGiven as mean 6 standard deviation.
xIndependent t-test.
kChi-squared test.
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Increased CSF levels of the biomarkers NFL, Ng,
YKL-40, and VILIP-1 have been found in AD and
correlate with neurodegeneration, suggesting a potential
use as a surrogate marker of synaptic and neuronal loss
[3,22–24]. Exercise and physical activity have been
linked to cognitive preservation and structural and
functional neuronal changes in humans [25]. However,
the underlying neurobiology is unknown. To gain new
insight into the molecular pathology in AD and possible
changes with physical exercise, several pathophysiological
pathways can be explored. The markers selected in this
study are recently investigated biomarkers of AD, and
very little is known of their ability to reflect changes in
the rate of neurodegeneration.
We hypothesized that EXE would have a stabilizing ef-
fect on the neurons and a dampening effect of astroglial acti-
vation resulting in less release to the CSF of the biomarkers
investigated. However, we found no significant effect of
EXE on our selected biomarkers. In a previous study, we
also did not find effect on Ab species and tau/p-tau [9].
These markers, however, may provide novel insight into
AD pathology and its progression [16,18,26]. The
biomarkers reflecting specific AD pathology in CSF (Ab
and tau/p-tau) change over the disease course in a pattern
that does not reflect neurodegeneration in a simple way mak-
ing them less suitable for longitudinal markers of disease
progression [27,28]. Because synaptic integrity plays a
central role in CF and synaptic loss has been shown to
correlate well with cognitive decline [29], biomarkers of
synaptic function may be of value in monitoring neurode-
generation, not only in AD but also in other neurodegenera-
tive diseases [29].
As mentioned earlier, the studied biomarkers could be
target biomarkers for measuring neurodegeneration in pa-
tients with AD, including effects of drug candidates and in-
terventions on AD pathophysiology. However, no changes
were found in biomarker levels in our 16-week aerobic exer-
cise intervention. The most straightforward interpretation of
these results is that they do not support any modulatory ef-
fect of physical exercise on AD pathophysiology, as
measured by selected biomarkers of neuronal and synaptic
integrity. The lack of a modulating effect of exercise on
our selected biomarkers might have other explanations. An-
imal studies in mice suggest that environmental stimulation,
including access to running wheels, improved cognition and
resulted in significant higher levels of brain Ng [30]. This
discrepancy may be because of full-length Ng is measured
in the brain, whereas in the CSF, there are several endoge-
nous cleavage products of Ng measured [21]. Also
YKL-40 has previously been studied in relation to exercise.
In a human study, the postexercise serum concentration of
YKL-40 was found to be upregulated both in RNA expres-
sion and in circulating protein concentration [31]. However,
in that setting, the elevated YKL-40 levels may have been
because of muscle contraction. One animal study found
that synapse-plasticity proteins, including NFL, were upre-
gulated in exercising rats [32], and previous studies have
shown that exercise promotes neurogenesis in the adult
Fig. 1. Spaghetti plots of concentration of biomarkers in cerebrospinal fluid at baseline and at 16 weeks follow-up in outcomemeasures. (A) Neurofilament light
(NFL), (B) neurogranin (Ng), (C) chitinase-3–like protein 1 (YKL-40), and (D) visinin-like protein-1 (VILIP-1). B: Baseline and F: 16-week follow-up.
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mouse brain [33,34]. Taken together these animal studies
suggest that exercise has a beneficial effect on synaptic
and neuronal integrity thereby promoting brain plasticity.
The reason for the negative results in our study could be
because of insufficient duration of the exercise. It could be
argued that 16 weeks of EXE is not a long enough
intervention to permanently alter the synaptic function in
the brain. Furthermore, any exercise mediated effect on the
synaptic level in AD could be so transient that the effect is
not able to manifest itself permanently or that the effect
wears of as soon as the subjects stop exercising. In addition,
information on changes of these biomarkers with
interventions or longitudinal changes is scarce. At the stage
of the disease in which the subjects included in this study
were studied, we do not know if it is reasonable to expect
changes in biomarkers reflecting neurodegeneration. The
neurodegeneration may be too advanced for a signal to be
picked up, if only subpopulations of neurons respond to EXE.
A further limitation of our study is the small number of
subjects. We had CSF available from 51 patients, of which
26 were randomized to the control group. Of the 25 exercise
participants, 16met the criteria “high-exercise subjects.” Re-
stricting the analysis to high-exercise subjects compared
with controls, did, however, not change the overall negative
findings. However, a power calculation (80% power) showed
that we had sufficient subjects in each group for detecting a
10% change in CSF concentration, based on the previous
studies, for Ng (eight subjects needed), YKL-40 (four sub-
jects needed), and NFL (nine subjects needed). Only our
VILIP-1 measurement is underpowered because 37 subjects
were needed to display a 10% changes in CSF concentration.
From Fig. 1 and the interassay CV, we can conclude that the
assays are fairly stable, and results are reproducible.
The use of EXE as a therapeutic approach for AD and
other dementias is an attractive add-on to conventional med-
ical treatment, and there seems to be a positive effect on
cognition [35]. The underlying effect is, however, largely
unknown [36], and more attention must be paid to the molec-
ular mechanism to understand and optimize this type of
treatment. Therefore, more studies investigating the effect
of type and length of physical exercise are needed to eluci-
date the molecular effect of EXE in AD.
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RESEARCH IN CONTEXT
1. Systematic review: Based on our previous finding in
other areas of the effects of physical exercise bio-
markers, we know that there is a beneficial effect of
physical exercise on memory, neuropsychiatric
symptoms, and physical function. However, we
have not found the underlyingmolecular mechanism.
2. Interpretation: We interpret our results as a clue to
finding the molecular mechanism, in understanding
effect of exercise in patients with Alzheimer’s dis-
ease (AD). Although our results are not a positive
find, we now know more exercise as a stabilizing
agent on synapse stability and integrity.
3. Future directions: The overall conclusion is that exer-
cise does have a beneficial effect on the selected bio-
markers; however, we recommend further studies in
other areas affected by AD that could be implicated
in the effect of physical exercise.
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